Compare
Genelux Corp vs Alaunos Therapeutics, Inc. vs PRF Technologies Ltd. vs Bioadaptives, Inc.
| Latest fiscal year | Genelux Corp GNLX | Alaunos Therapeutics, Inc. TCRT | PRF Technologies Ltd. PRFX | Bioadaptives, Inc. BDPT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $8.0K | $5.0K | $17.0K | $18.3K |
| Revenue growth (YoY) | 0.0% | -50.0% | n/a | +44.3% |
| Gross margin | n/a | n/a | -311.8% (computed) | 68.4% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$32.15M | -$4.18M | -$5.02M | -$1.56M |
| EPS (Diluted) | -$0.86 | -$2.20 | -$7.47 | -$0.15 |
| Operating cash flow | -$25.27M | -$2.87M | -$3.96M | -$516.0K |
| Free cash flow | -$26.37M | -$2.97M | -$3.96M | -$534.0K |
| Cash & equivalents | $5.33M | $1.39M | $3.12M | $215.2K |
| Total assets | $19.03M | $2.97M | $12.00M | $225.9K |
| Total liabilities | $7.48M | $813.0K | $2.71M | $2.36M |
| Shareholders' equity | $11.54M | $2.15M | $8.54M | -$2.13M |
| Return on year-end equity | -278.5% | -194.0% | -58.8% | n/a |
| Shares outstanding | 38.14M | 2.35M | 830.6K | 12.01M |
Revenue, most recent five fiscal years
| Fiscal year | Genelux Corp | Alaunos Therapeutics, Inc. | PRF Technologies Ltd. | Bioadaptives, Inc. |
|---|---|---|---|---|
| Latest | $8.0K Ended 2025-12-31 | $5.0K Ended 2025-12-31 | $17.0K Ended 2025-12-31 | $18.3K Ended 2025-12-31 |
| 1 year earlier | $8.0K Ended 2024-12-31 | $10.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | $12.7K Ended 2024-12-31 |
| 2 years earlier | $170.0K Ended 2023-12-31 | $5.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $28.6K Ended 2023-12-31 |
| 3 years earlier | $11.07M Ended 2022-12-31 | $2.92M Ended 2022-12-31 | n/a | $17.2K Ended 2022-12-31 |
| 4 years earlier | n/a | $398.0K Ended 2021-12-31 | n/a | $19.8K Ended 2021-12-31 |